---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-099328"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2026-03-10T23:59:59+00:00"
generated_at: "2026-05-15T16:43:28.220102+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Q32 Bio reports Q4 net income of $57.7M; Phase 2a SIGNAL-AA enrollment complete; cash runway into Q4 2027

## Summary
- Completed enrollment in Part B of SIGNAL-AA Phase 2a for alopecia areata; 36-week topline data expected mid-2026.
- Completed $10.5M registered direct offering in Feb 2026; cash $48.3M at Dec 31, 2025, plus RDO and milestones fund ops into Q4 2027.
- Sold ADX-097 to Akebia Therapeutics for $12M upfront/near-term milestone; up to $592M in milestones plus royalties.
- Terminated all remaining obligations to Amgen via one-time equity grant; no future payments to Amgen.
- Net income $57.7M in Q4 2025 and $29.8M for FY 2025 vs net loss prior year; EPS $4.58 diluted.

## SEC filing metadata
- accession: 0001193125-26-099328
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2026-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000119312526099328/0001193125-26-099328-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000119312526099328/qttb-20260310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-099328
- JSON: https://secwatch.observer/filing/0001193125-26-099328.json
- Plain text: https://secwatch.observer/filing/0001193125-26-099328.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.